Replimune to Present at Chardan’s 3rd Annual Genetic Medicines Conference
October 01 2019 - 8:00AM
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company
developing oncolytic immuno-gene therapies derived from its
Immulytic™ platform, today announced that Robert Coffin, Ph.D.,
Chief Executive Officer and Director of Replimune, will present and
host one-on-one meetings at Chardan’s 3rd Annual Genetic Medicines
Conference being held in New York City. The Company is scheduled to
present on Monday, October 7, 2019 at 4:15 PM ET.
About Replimune Replimune Group, Inc.,
headquartered in Woburn, MA, was founded in 2015 to develop the
next generation of “oncolytic immune-gene therapies” for the
treatment of cancer. Replimune is developing novel, proprietary
therapeutics intended to improve the direct cancer-killing effects
of selective virus replication and the potency of the immune
response to the tumor antigens released. The Company’s Immulytic™
platform is designed to maximize systemic immune activation, in
particular to tumor neoantigens, through robust viral-mediated
immunogenic tumor cell killing and the delivery of optimal
combinations of immune-activating proteins to the tumor and
draining lymph nodes. The approach is expected to be highly
synergistic with immune checkpoint blockade and other approaches to
cancer treatment. Replimune intends to progress these therapies
rapidly through clinical development in combination with other
immuno-oncology products with complementary mechanisms of action.
For more information, please visit www.replimune.com
Replimune ContactPamela Esposito,
Ph.D.Replimune Group, Inc.617.233.6988pamela@replimune.com
Investor Inquiries Chris BrinzeyWestwicke
Partners, an ICR Company339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen Goldenberg Verge
Scientific
Communications917.548.1582agoldenberg@vergescientific.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Sep 2023 to Sep 2024